newsfilter
← Latest News
GlobeNewswire·

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class αvβ3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation antibody-drug